Kytril and Ejection fraction - a phase IV clinical study of FDA data

Summary:

Ejection fraction is reported as a side effect among people who take Kytril (granisetron hydrochloride), especially for people who are female, 50-59 old, also take Taxol, and have Breast cancer.

The phase IV clinical study analyzes which people have Ejection fraction when taking Kytril. It is created by eHealthMe based on reports of 10,727 people who have side effects when taking Kytril from the FDA, and is updated regularly.

What is Kytril?

Kytril has active ingredients of granisetron hydrochloride. eHealthMe is studying from 10,766 Kytril users. Check the latest studies of Kytril.

What is Ejection fraction?

Ejection fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat) is found to be associated with 375 drugs and 324 conditions by eHealthMe. Check the latest studies of Ejection fraction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

10,727 people reported to have side effects when taking Kytril.
Among them, 17 people (0.16%) have Ejection fraction.

$Could Kytril cause Ejection fraction?$

Among these 17 people:

What is the gender of people who have Ejection fraction when taking Kytril? *

female: 100 %
male: 0.0 %

What is the age of people who have Ejection fraction when taking Kytril? *

What are other drugs people take besides Kytril? *

What are other side effects people have besides Ejection fraction? *

Weight Loss: 13 people, 76.47%
Infection: 13 people, 76.47%
Haemorrhage (bleeding): 13 people, 76.47%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 13 people, 76.47%
Heart Rate Decreased: 13 people, 76.47%
Hepatic Cyst: 13 people, 76.47%
Hyperplasia (enlargement of an organ or tissue): 13 people, 76.47%
Impaired Healing: 13 people, 76.47%
Inflammation: 13 people, 76.47%
Nausea (feeling of having an urge to vomit): 13 people, 76.47%

What are the existing conditions these people have? *

Pain: 13 people, 76.47%
Oedema (fluid collection in tissue): 13 people, 76.47%
Metastasis (spreadable cancer to other organ from origin): 13 people, 76.47%
Metastases To Bone (cancer spreads to bone): 13 people, 76.47%
Depression: 13 people, 76.47%
Breast Cancer: 13 people, 76.47%
Hepatic Neoplasm (liver tumour): 1 person, 5.88%
Diabetes: 1 person, 5.88%
Cardiac Disorder: 1 person, 5.88%
Carcinoid Tumor Of The Gastrointestinal Tract: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Kytril and have Ejection fraction?

- Check whether Ejection fraction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kytril:

Kytril (10,766 reports)

Browse all side effects of Kytril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ejection fraction:

Ejection fraction (375 drugs)

Browse all the conditions that are associated with Ejection fraction:

Ejection fraction (324 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on granisetron hydrochloride (the active ingredients of Kytril) and Kytril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.